Arcus Biosciences (RCUS) Share-based Compensation (2017 - 2026)

Arcus Biosciences' Share-based Compensation history runs 10 years deep, the most recent figure standing at $19.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 18.75% year-over-year to $19.0 million; the TTM figure through Mar 2026 stood at $63.0 million (down 12.5% YoY), while the FY2025 annual figure was $60.0 million, down 21.05% from the prior year.
• Share-based Compensation was $19.0 million for Q1 2026 at Arcus Biosciences, up from $15.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $20.0 million in Q1 2024 to a low of $14.0 million in Q3 2025.
• Historically, Share-based Compensation has averaged $17.3 million across 5 years, with a median of $17.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 33.22% in 2022, then declined 26.32% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $17.0 million in 2022, then climbed by 5.88% to $18.0 million in 2023, then declined by 5.56% to $17.0 million in 2024, then declined by 11.76% to $15.0 million in 2025, then rose by 26.67% to $19.0 million in 2026.
• The last three Share-based Compensation figures came in at $19.0 million (Q1 2026), $15.0 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.